T3 may promote cancer cell proliferation says study. Triiodothyronine was found to enhance the MCF-7 and T47-D breast cancer cell lines. The conclusion of the abstract discusses a role of T3 in breast cancer development and progression. This likely has more to do with progression than development through increased metabolism of the cell lines.
Significant suppression of serum concentrations of 3,5,3'-triiodothyronine (T3) and elevation of serum concentrations of 3,3',5'-triiodothyronine (rT3) were seen
The mechanism or the biological significance of such a diversion of T4, from the normally occurring conversion to highly potent T3, to the generation of poorly calorigenic rT3 in systemic illness
such a change in the metabolism of T4 can be reversible.
T3 may have effects similar to Estradiol in breast cell proliferation. This may be, but what about the effects on increased metabolism and resultant fat loss which leads to reduce inflammation...I believe this is all about context of the environment in the individual and the importance of customizing therapy.
Article points to potential chemosensitizing effect of T3 in cancer treatment. Chemotherapy with increased metabolic demand with T3 may improve cancer kill rate.
Only abstract available here. In vitro study finds that rT3 decreased the metabolic effect of T3. This gives the impression that rT3 has an antagonist effect to T3 on the receptor.
IV T3 was given to patients with chronic heart failure. What the study found may surprise you: improved heart function (ventricular), improved BNP, decrease heart rate, no side effects. T3 has been shown to be more predictive of cardiac death in those with cardiac disease, than elevated lipids or decreased ejection fraction.
More than 80% of the biologically active hormone triiodothyronine (T3) derives from peripheral conversion of prohormone thyroxine
(T4) secreted by the thyroid gland
Low thyroid hormone concentrations, in particular low serum T3 concentrations, are a common finding in patients with nonthyroidal
illnesses, including cardiac disorders
a direct relationship
between low circulating levels of T3 and adverse prognosis of cardiac patients
The present study clearly shows the existence of a strong association between the reduction of biologically active T3 and
mortality in a large population of cardiac hospitalized patients
highly significant increase in the incidence
of cardiac and cumulative deaths in patients with low T3 compared with patients with normal T3 levels
the relevance of the low T3 state as a strong, independent predictor of mortality in cardiac patients
low T3 concentrations are a strong independent predictive marker of poor prognosis in cardiac patients
low T3 associated with poor prognosis in cardiac patients. Poor prognosis = death. T3 is important in cardiac remodeling, which is inherently important with cardiac disease.